Madhav Bhutada says overdependence on large CDMOs and delayed engagement can increase development costs by up to 40% and slow clinical progress
India already has talent, digital infrastructure, entrepreneurial energy, clinical expertise, and policy momentum. The next phase demands coordinated execution and building institutions that can hold the ecosystem together over time
Discussions are likely to centre on how the country can move up the pharmaceutical value chain
The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows
The academy has secured partnerships with 15 esteemed hospitals
In his new role as Managing Director India and Global Head, Partnerships and Innovative Finance, Singh will oversee the financial, human, and operational functions of the India office
The company plans an aggressive partnering push, with 62 pre-scheduled meetings over four days, focused on out-licensing, co-development, and strategic collaborations with global pharmaceutical and biotech players
Country’s deep scientific talent pool and its growing role as a clinical trial destination makes it central to how Parexel serves sponsors
Veteran health innovation and policy leader to drive biotechnology innovation, startup growth and commercialization of indigenous technologies
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
